In 2026, both CVS and Intel showed strong turnaround results but faced stock sell-offs for different reasons. Intel's decline stems from doubts about its 18A manufacturing roadmap and competitive pressure, while CVS's drop relates to a cautious 2027 forecast. For retirees needing reliable income, CVS is preferable due to its consistent earnings, 2.9% dividend yield, and lower stock volatility. Intel offers no dividend, carries higher risk, and requires investors to bet on future execution success. Retirees should watch Intel's production progress and CVS's 2027 outlook for future signals.
CVS Health has made the updated 2026-2027 flu vaccines available at CVS Pharmacy and MinuteClinic locations nationwide. Over 60% of consumers are likely to get a flu shot this season, according to a CVS survey, highlighting strong demand. The CDC rec...
Health insurance stocks are rising sharply following strong second-quarter earnings and improved cost management. UnitedHealth Group reported over $5 billion in net income with a lower medical care ratio, signaling better control of medical expenses....
CVS Health's integrated healthcare model across insurance, pharmacy, and clinical care supports its long-term margin recovery and revenue growth. The recent stock selloff has lowered its price-to-earnings ratio to 11.78, making it an attractive buy w...
